EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals (NASDAQ:EYPT)

Core Viewpoint - EyePoint Pharmaceuticals has granted stock options to new employees as inducement awards outside its 2023 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4) [1][2]. Company Overview - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases [3]. - The company's lead product candidate, DURAVYU™, is a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [3]. - DURAVYU is currently undergoing evaluation in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD), with topline data for the LUGANO trial expected in mid-2026 [3]. - The first patient dosing in pivotal Phase 3 clinical trials for diabetic macular edema (DME) is anticipated in the first quarter of 2026 [3]. Stock Options Details - The company granted stock options to purchase up to 31,000 shares of common stock to seven new employees on November 14, 2025 [2]. - The exercise price for the options is set at $11.58 per share, which is the closing price of EyePoint's common stock on the grant date [2]. - The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years [2].